We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Point-of-Care Urine Lipoarabinomannan Testing to Guide Tuberculosis Treatment Among Severely Ill Inpatients With Human Immunodeficiency Virus in Real-World Practice: A Multicenter Stepped Wedge Cluster-Randomized Trial From Ghana.
- Authors
Åhsberg, Johanna; Puplampu, Peter; Kwashie, Augustine; Commey, Joseph Oliver; Ganu, Vincent Jessey; Omari, Michael Amo; Adusi-Poku, Yaw; Andersen, Åse Bengård; Kenu, Ernest; Lartey, Margaret; Johansen, Isik Somuncu; Bjerrum, Stephanie
- Abstract
Background The lateral flow urine lipoarabinomannan assay, Determine TB LAM (Determine LAM), offers the potential for timely tuberculosis (TB) treatment among people with human immunodeficiency virus (PWH). Methods In this cluster-randomized trial, Determine LAM was made available with staff training with performance feedback at 3 hospitals in Ghana. Newly admitted PWH with a positive World Health Organization four-symptom screening for TB, severe illness, or advanced HIV were enrolled. The primary outcome was days from enrollment to TB treatment initiation. We also reported the proportion of patients with a TB diagnosis, initiating TB treatment, all-cause mortality, and Determine LAM uptake at 8 weeks. Results We enrolled 422 patients including 174 (41.2%) in the intervention group. The median CD4 count was 87 (interquartile range [IQR], 25–205) cells/μL, and 32.7% were on antiretroviral therapy. More patients were diagnosed with TB in the intervention compared with the control group: 59 (34.1%) versus 46 (18.7%) (P <.001). Time to TB treatment remained constant, but patients were more likely to initiate TB treatment (adjusted hazard ratio, 2.19 [95% CI, 1.60–3.00]) during the intervention. Of patients with a Determine LAM test available, 41 (25.3%) tested positive. Of those, 19 (46.3%) initiated TB treatment. Overall, 118 patients had died (28.2%) at 8 weeks of follow-up. Conclusions The Determine LAM intervention in real-world practice increased TB diagnosis and the probability of TB treatment but did not reduce time to treatment initiation. Despite high uptake, only half of the LAM-positive patients initiated TB treatment.
- Subjects
GHANA; HIV infection complications; EVALUATION of human services programs; TUBERCULOSIS diagnosis; TUBERCULOSIS mortality; TUBERCULOSIS treatment; HIV-positive persons; LIPOPOLYSACCHARIDES; CONFIDENCE intervals; POINT-of-care testing; CD4 antigen; ANTIRETROVIRAL agents; RANDOMIZED controlled trials; DESCRIPTIVE statistics; RESEARCH funding; URINALYSIS; STATISTICAL sampling; ODDS ratio; PROBABILITY theory
- Publication
Clinical Infectious Diseases, 2023, Vol 77, Issue 8, p1185
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciad316